Race-Associated EGFR and KRAS Mutation Profiles in Lung Adenocarcinoma
Genes · 16.08.2026 · 17 (8) · 960
DOI: 10.3390/genes17080960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 16.08.2026. Verfasst von Lovyanne Vergel de Dios und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, The University of Texas Rio Grande Valley, Edinburg, TX 78541, USA. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Alzheimer association, NIH HHS.
Abstract (Originalsprache)
Background
Lung adenocarcinoma (LUAD) is the most prevalent histologic subtype of non-small cell lung cancer (NSCLC) and exhibits considerable molecular heterogeneity. Among the most clinically significant driver alterations are mutations in EGFR and KRAS, both of which influence treatment selection and oncologic outcomes. The prevalence of these mutations varies by race, yet racial minority populations remain underrepresented in genomic studies. EGFR alterations are more frequently observed in Asian patients, while KRAS mutations predominate in non-Asian cohorts. This study aimed to characterize race-associated differences in driver mutation prevalence among Asian, Black, and White patients with LUAD.
Methods
A retrospective secondary cohort analysis was performed using publicly available clinicogenomic data from the Lung Adenocarcinoma Met Organotropism cohort, accessed via cBioPortal, comprising 2653 tumor samples. Patients were stratified by self-reported race into Asian, Black, and White cohorts; cases with missing race data were denoted as either other or unknown. Mutation frequencies for EGFR, KRAS, and TP53 were extracted from OncoPrint cohort study views and compared descriptively across groups.
Results
Distinct race-associated differences in driver mutation prevalence were observed. Asian patients exhibited the highest frequency of EGFR alterations (64%), compared with Black (41%) and White (28%) cohorts. In contrast, KRAS mutations were least prevalent in Asian patients (10%) and more frequent in White (33%) and Black (23%) cohorts, indicating an inverse distribution between Asian and non-Asian populations. TP53 mutation prevalence was similar in Asian (52%) and White (53%) cohorts but was notably higher in Black patients (65%).
Conclusions
Asian patients with LUAD exhibit a distinct molecular profile characterized by EGFR predominance, with direct implications for eligibility for EGFR-targeted tyrosine kinase inhibitor therapy. Black patients may also benefit from EGFR-based targeted therapies, but lack of large genomic data on Black populations warrants further investigation. White cohorts display a KRAS-dominant mutation pattern, suggesting divergent tumorigenic pathways and the potential need for alternative therapeutic strategies. The elevated TP53 frequency in Black patients remains to be further characterized. These findings support integrating race-associated genomic profiling into precision oncology frameworks to improve treatment selection and reduce disparities in outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, The University of Texas Rio Grande Valley, Edinburg, TX 78541, USA.
- South Texas Center of Excellence in Cancer Research, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78540, USA.
- Medicine and Oncology ISU, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78540, USA.
ORCID-Profile: Lovyanne Vergel de Dios, Catherine Wu, Manish K Tripathi
Förderung
- NIGMS NIH HHS
- Alzheimer association
- NIH HHS
- Cancer Prevention and Research Institute of Texas
- NIH/NIGMS
- ST-CECR-Project 2
- Alzheimer’s Association
- UTRGV SOM Startup
Zitieren
APA
Dios, L. V., Wu, C., Shaham, S. H., & Tripathi, M. K. (2026). Race-Associated EGFR and KRAS Mutation Profiles in Lung Adenocarcinoma. Genes, 17(8), 960. https://doi.org/10.3390/genes17080960
Vancouver
Dios LV, Wu C, Shaham SH, Tripathi MK. Race-Associated EGFR and KRAS Mutation Profiles in Lung Adenocarcinoma. Genes. 2026;17(8):960. doi:10.3390/genes17080960
BibTeX
@article{Dios2026,
author = {Dios, Lovyanne Vergel de and Wu, Catherine and Shaham, Salique H and Tripathi, Manish K},
title = {Race-Associated EGFR and KRAS Mutation Profiles in Lung Adenocarcinoma},
journal = {Genes},
year = {2026},
volume = {17},
number = {8},
pages = {960},
doi = {10.3390/genes17080960}
}
EUVIMED